Detalhe da pesquisa
1.
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
J Infect Dis
; 228(6): 734-741, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210741
2.
Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
J Infect Dis
; 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37970668
3.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
4.
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
PLoS Med
; 18(10): e1003769, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597298
5.
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
N Engl J Med
; 388(9): 857-859, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734884
6.
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
Antimicrob Agents Chemother
; 62(11)2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30150460
7.
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
Biologicals
; 50: 81-86, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844541
8.
Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).
J Infect Dis
; 213(6): 922-9, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26655841
9.
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
Vaccine
; 42(7): 1777-1784, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365482
10.
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Lancet Infect Dis
; 24(6): 581-593, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460525
11.
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Vaccine
; 41(29): 4280-4286, 2023 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271706
12.
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Sci Rep
; 13(1): 19176, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932354
13.
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Expert Rev Vaccines
; 22(1): 501-517, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246757
14.
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical Trial.
JAMA Pediatr
; 2023 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523166
15.
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Lancet Infect Dis
; 22(11): 1565-1576, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35963274
16.
Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines.
Euro Surveill
; 21(45)2016 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27918259
17.
A systematic review and meta-analysis of the effectiveness of LAIV4 and IIV in children aged 6 months to 17 years during the 2016-2017 season.
Vaccine
; 38(18): 3405-3410, 2020 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31917037
18.
A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.
Vaccine
; 38(5): 1001-1008, 2020 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31796225
19.
Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink.
BMJ Open
; 8(12): e023118, 2018 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30530581
20.
Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial.
J Asthma Allergy
; 11: 181-192, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510434